Form 424B5 - Prospectus [Rule 424(b)(5)]
30 Décembre 2024 - 12:20PM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-274546
PROSPECTUS SUPPLEMENT
(To Prospectus Supplement dated September 13, 2024 to Prospectus dated
September 15, 2023)
AEYE, INC.
Up to $5,230,000
Common Stock
______________
This Prospectus Supplement amends and supplements
the information in the prospectus, dated September 15, 2023 (the “Prospectus”), filed with the Securities and Exchange Commission
as a part of our registration statement on Form S-3 (File No. 333-274546), as previously supplemented by our prospectus supplement, dated
September 13, 2024 (the “Prior Supplement” and together with the Prospectus, the “Prior Prospectus”), relating
to the offer and sale of shares of our common stock having an aggregate offering price of up to $2,600,000 pursuant to the terms of At
Market Issuance Sales Agreement, dated September 12, 2024 (the “Sales Agreement”), with A.G.P./Alliance Global Partners (“A.G.P.”).
This Prospectus Supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the
extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This Prospectus Supplement
is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements
thereto.
We are filing this Prospectus Supplement to
amend the Prior Prospectus to update the maximum amount of shares that we are eligible to sell under our Registration Statement pursuant
to the Sales Agreement under General Instruction I.B.6 of Form S-3. As a result of these limitations and the current public float of our
common stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate
offering price of up to $5,230,000 from time to time through A.G.P. In the event that we may sell additional amounts under the Sales Agreement
in accordance with General Instruction I.B.6, we will file another prospectus supplement prior to making such additional sales. This Prospectus
Supplement amends and/or supplements only those sections of the Prior Prospectus as listed in this Prospectus Supplement, and all other
sections of the Prior Prospectus remain as is.
We are an “emerging growth company”
and “smaller reporting company” as defined under U.S. federal securities laws and are subject to reduced public company reporting
requirements. Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “LIDR.” The
last sale price of our common stock, as reported on Nasdaq on December 27, 2024, was $2.04 per share.
As of December 27, 2024, the aggregate
market value of our outstanding shares of common stock held by non-affiliates, or public float, was determined to be $23,235,139
based on 12,005,988 shares of common stock outstanding, of which 616,214 are held by non-affiliates, and at a price of
$2.04 per share, the closing price of our common stock on December 27, 2024. In no event will the aggregate market value of
securities sold by us or on our behalf pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar month period
immediately prior to, and including, the date of any such sale exceed one-third of the aggregate market value of our shares of
common stock held by non-affiliates, so long as the aggregate market value of our common stock held by non-affiliates is less than
$75,000,000. During the prior 12 calendar month period that ends on, and includes, December 27, 2024, we have
sold $5,105,173 of our securities pursuant to General Instruction I.B.6 of Form S-3.
______________________________________
Investing in our
common stock involves a high degree of risk. See the “Risk Factors” section beginning on page S-6 of the Prior
Supplement and the documents incorporated by reference into this Prospectus Supplement and the Prior Prospectus, as they may be
amended, updated or supplemented periodically in our reports filed with the Securities and Exchange Commission, before investing in our common stock.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this Prospectus Supplement or the
Prior Prospectus are truthful or complete. Any representation to the contrary is a criminal offense.
A.G.P.
The date of this prospectus supplement is
December 30, 2024
AEye (NASDAQ:LIDRW)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
AEye (NASDAQ:LIDRW)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025